DE60208186D1 - Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen - Google Patents

Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen

Info

Publication number
DE60208186D1
DE60208186D1 DE60208186T DE60208186T DE60208186D1 DE 60208186 D1 DE60208186 D1 DE 60208186D1 DE 60208186 T DE60208186 T DE 60208186T DE 60208186 T DE60208186 T DE 60208186T DE 60208186 D1 DE60208186 D1 DE 60208186D1
Authority
DE
Germany
Prior art keywords
chinazole
chinazolin
integrin
treatment
mediated illnesses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60208186T
Other languages
English (en)
Other versions
DE60208186T2 (de
Inventor
William J Hoekstra
Edward C Lawson
Michael J Costanzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Mcneil Pharmaceutical Research Inc
Original Assignee
Ortho Mcneil Pharmaceutical Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharmaceutical Research Inc filed Critical Ortho Mcneil Pharmaceutical Research Inc
Application granted granted Critical
Publication of DE60208186D1 publication Critical patent/DE60208186D1/de
Publication of DE60208186T2 publication Critical patent/DE60208186T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60208186T 2001-04-09 2002-04-05 Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen Expired - Fee Related DE60208186T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28264801P 2001-04-09 2001-04-09
US282648P 2001-04-09
PCT/US2002/010596 WO2002081467A1 (en) 2001-04-09 2002-04-05 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders

Publications (2)

Publication Number Publication Date
DE60208186D1 true DE60208186D1 (de) 2006-01-26
DE60208186T2 DE60208186T2 (de) 2006-08-24

Family

ID=23082482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60208186T Expired - Fee Related DE60208186T2 (de) 2001-04-09 2002-04-05 Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen

Country Status (5)

Country Link
US (1) US7081460B2 (de)
EP (1) EP1389205B1 (de)
JP (1) JP2004529918A (de)
DE (1) DE60208186T2 (de)
WO (1) WO2002081467A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1556357A4 (de) * 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (de) * 2002-08-21 2006-08-30 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
CA2529486A1 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
RS52918B (en) 2004-04-02 2014-02-28 The Regents Of The University Of California PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2635531C (en) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
DE102007008484A1 (de) * 2007-02-19 2008-08-21 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Pharmazeutische Zubereitung zur Bekämpfung von Metastasen
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
JP6038212B2 (ja) * 2015-03-18 2016-12-07 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
CN104725325B (zh) * 2015-04-10 2017-01-18 温州大学 一种2‑(1‑苯乙基)喹唑啉酮及其催化合成方法
MX2019000043A (es) * 2016-07-05 2019-07-04 Univ Rockefeller Antagonistas de integrina de tetrahidronaftiridinpentanamida.
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830555A1 (de) * 1978-07-12 1980-03-06 Bayer Ag Chinazolinonyl-verbindungen
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
EP0617705B1 (de) * 1991-11-22 1997-09-24 Yeda Research And Development Company, Ltd. Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
US6268380B1 (en) * 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
US6380215B1 (en) 1993-09-22 2002-04-30 Fujisawa Pharmaceutical Co., Ltd Beta-alanine derivative and a process for the preparation thereof
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BR9510360A (pt) * 1994-12-23 1997-12-23 Thomae Gmbh Dr K Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
CA2227265C (en) 1995-08-14 2012-01-03 The Scripps Research Institute Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
ES2161373T3 (es) 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
WO1997015567A1 (de) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
ATE212978T1 (de) * 1996-03-29 2002-02-15 Searle & Co Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ATE421952T1 (de) 1996-05-01 2009-02-15 Ortho Mcneil Pharm Inc Carboxamidderivate von pyrrolidin, piperidin und hexahydropiperizin für behandlung von thrombosen
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE69720062D1 (de) 1996-12-09 2003-04-24 Lilly Co Eli Integrin antagonisten
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
WO1999058501A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
GT199900185A (es) * 1998-11-06 2001-04-18 Novedosa pirimidin-4-enamina como fungicida.
EP1208101A4 (de) 1999-08-06 2003-03-19 Smithkline Beecham Corp Zur behandlung von schlaganfällen nützliche vitronektin-rezeptor-antagonisten

Also Published As

Publication number Publication date
US20030139398A1 (en) 2003-07-24
EP1389205A1 (de) 2004-02-18
JP2004529918A (ja) 2004-09-30
WO2002081467A1 (en) 2002-10-17
DE60208186T2 (de) 2006-08-24
US7081460B2 (en) 2006-07-25
EP1389205B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60208794D1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
ATE381347T1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee